|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, the efficacy of these agents in inhibiting a broad range of inflammatory responses suggests PPARgamma agonists may provide a novel therapeutic approach to AD.
|
10632585 |
2000 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that PPARgamma-controlled mechanisms should be explored further as potential drug targets for Alzheimer's disease treatment.
|
15574741 |
2004 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PPARgamma polymorphism did not influence the risk of AD.
|
15666037 |
2005 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent data indicate that PPARgamma (peroxisome proliferator-activated receptor gamma) could be involved in the modulation of the amyloid cascade causing Alzheimer's disease.
|
15946122 |
2005 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
These findings demonstrate that PPARgamma agonists attenuate the effects of Abeta on LTP, and support the potential use of these agents to alleviate the symptoms of Alzheimer's disease.
|
15993441 |
2005 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Our data strongly support a major role of PPARgamma in the modulation of amyloid-beta generation by inflammation and suggest that the protective mechanism of NSAIDs in AD involves activation of PPARgamma and decreased BACE1 gene transcription.
|
16407166 |
2006 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data strongly support a major role of PPARgamma in the modulation of amyloid-beta generation by inflammation and suggest that the protective mechanism of NSAIDs in AD involves activation of PPARgamma and decreased BACE1 gene transcription.
|
16407166 |
2006 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Our data strongly support a major role of PPARgamma in the modulation of amyloid-beta generation by inflammation and suggest that the protective mechanism of NSAIDs in AD involves activation of PPARgamma and decreased BACE1 gene transcription.
|
16407166 |
2006 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARgamma agonists have been shown to be efficacious in animal models of Alzheimer's disease, stroke, multiple sclerosis, Parkinson's disease and amyotrophic lateral sclerosis.
|
16766086 |
2006 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, recent evidence indicates that beneficial effects of non-steriodal anti-inflammatory drugs on the progression of AD are mediated--at least in part--by effects on the peroxisome proliferator-activated receptor-gamma response element present in the BACE1 promoter.
|
16904810 |
2006 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on these findings, the gene encoding PPARgamma can be viewed as an interesting candidate in AD.
|
16988505 |
2006 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Though this difference was borderline significant after correction for multiple comparisons, our results suggest a possible involvement of the PPAR-gamma gene in susceptibility to late-onset AD in octogenarians.
|
17270153 |
2007 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci.
|
17440948 |
2007 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
In a replication study, we confirmed significant association of SNPs within three genes--PPARgamma, SOS2, and PCK1--with Alzheimer's disease.
|
17440948 |
2007 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, PPARgamma may act to modulate multiple pathophysiological mechanisms that contribute to Alzheimer's disease, and represents an attractive therapeutic target for the treatment of the disease.
|
18072811 |
2008 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that PPARG gene does not play a major role in the genetic predisposition to AD in the Finnish population.
|
18573313 |
2008 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using aged ( approximately 16 months) amyloid precursor protein (APP) transgenic mice that exhibit increased production of the amyloid-beta (Abeta) peptide and severe cerebrovascular and memory deficits, we examined the capacity of in vivo treatments with the antioxidants N-acetyl-L-cysteine (NAC) and tempol, or the peroxisome proliferator-activated receptor gamma agonist pioglitazone to rescue cerebrovascular function and selected markers of AD neuropathology.
|
18784309 |
2008 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical trials with rosiglitazone, a potent agonist at peroxisome proliferator-activated receptor gamma (PPARgamma) suggest an improvement of cognitive function in Alzheimer's disease (AD) patients.
|
19109927 |
2009 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We utilised real time autoradiography and immunohistochemistry to investigate microglial activation and the potential anti-inflammatory effects of PPARgamma agonists in the Thy-1 APP695swe/Thy-1 PS-1.M146V (TASTPM) overexpressing transgenic mouse model of AD.
|
19320004 |
2009 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that PPARgamma transcriptionally induces IDE expression which provides a novel mechanism for the use of PPARgamma agonists in both DM2 and AD therapies.
|
19383491 |
2009 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the functional PPAR-gamma Pro12Ala polymorphism may modify the age at onset of AD.
|
19631630 |
2009 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that PPAR-γ genetic variants may modify the risk of AD in an APOE ε4 allele-dependent fashion.
|
19660836 |
2011 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical studies suggest that agonists at peroxisome proliferator-activated receptor gamma (PPARgamma) may exert beneficial effects in patients with mild-to-moderate Alzheimer's disease (AD), but the mechanism for the potential therapeutic interest of this class of drugs has not yet been elucidated.
|
20336061 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects.
|
20733306 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
As a transcription factor binding site of the BACE1 promoter, peroxisome proliferator-activated receptor-γ (PPARγ) response element regulates the activity of the BACE1 promoter activity, indicating that PPARγ may become a potential target for Alzheimer's disease treatment.
|
22166376 |
2012 |